NCT05390255

Establishment of Precise Diagnosis and Treatment System for Refractory Chronic Rhinosinusitis

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 87 (estimated)
• Sponsor: Beijing Tongren Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Chronic rhinosinusitis that recurs after adequate surgery and conventional medical treatment is called refractory chronic rhinosinusitis (RCRS). Omalizumab and oral glucocorticoid therapy can play an important role in the treatment of RCRS, but there is still a lack of comparative studies on the efficacy and safety of the two. In addition, biomarkers are a hotspot in RCRS research, but there is still a lack of studies on changes in marker expression with disease progression and treatment. In this study, patients aged 18-70 who were diagnosed with CRS were consecutively enrolled, and the patients were divided into RCRS and non-RCRS groups according to pathological results. The patients in the RCRS group were randomly divided (1:1:1) into the nasal spray hormone therapy group, the nasal spray hormone therapy + oral hormone therapy group, and the nasal spray hormone therapy + omalizumab therapy group by a multi-center, randomized, controlled study. The patients were treated for 6 months and followed up for 6 months after treatment. Clinical data such as symptom score and endoscopic score before and after treatment were collected, adverse events were recorded, and the differences in efficacy and safety among the groups were compared. Non-invasive samples such as nasal secretions and exfoliated cells were collected, and the expression and variation of different immune intrinsic markers were explored combined with follow-up results. The development of this project contributes to the establishment of a precise diagnosis and treatment system for refractory chronic sinusitis.

Conditions

• Sinusitis

Interventions

Type	Name	Description
DRUG	Mometasone furoate nasal spray hormone	This group of patients received mometasone furoate nasal spray hormone treatment throughout the study.
DRUG	Mometasone furoate nasal spray hormone + oral hormone	The patients in this group were given oral hormone therapy for 14 days in the first month and the fourth month under the background of mometasone furoate nasal spray hormone treatment throughout the course.
DRUG	Mometasone furoate nasal spray hormone + omalizumab	The patients in this group were injected with omalizumab once a month under the background of mometasone furoate nasal spray hormone treatment, for a total of 6 times.

Timeline

• Start date: 2022-05-25
• Primary completion: 2024-12-31
• Completion: 2024-12-31
• First posted: 2022-05-25
• Last updated: 2022-05-25

Locations

1 site across 1 country: China